Literature DB >> 10650136

Nitric oxide synthase and glutamate receptor immunoreactivity in the rat spinal trigeminal neurons expressing Fos protein after formalin injection.

S Leong1, H Liu, J Yeo.   

Abstract

Although recent studies implicated glutamate receptors and nitric oxide in nociception, much still needs to be known about their localisation in neurons involved in nociceptive transmission from the orofacial region. In this study, c-fos expression indicated by Fos immunohistochemistry in the caudal spinal trigeminal nucleus induced by subcutaneous injection of formalin into the lateral face of the rat was used as a marker for nociceptive neurons. The study sought to determine whether Fos-positive neurons express nitric oxide synthase, glutamate N-methyl-D-aspartate type receptor subunit 1, and glutamate alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid type receptor subunit 2/3; and whether they project to the thalamus. After formalin injection, many Fos-positive nuclei appeared in the superficial laminae of the ipsilateral trigeminal nucleus. Confocal laser scanning microscope revealed that almost all neurons with Fos immunofluorescent nuclei were colocalised with N-methyl-D-aspartate receptor 1, 94% with glutamate receptor 2/3 and 14% with nitric oxide synthase. Some of them were closely related to neurons labelled by nitric oxide synthase. Lastly, some of the Fos-positive neurons were labelled by tetramethylrhodamine-dextran injected into the trigeminothalamic tract or the thalamic region. The results suggested that activation of N-methyl-D-aspartate receptor 1 and glutamate receptor 2/3 upon glutamate release in response to noxious stimulation to the orofacial region might mediate c-fos expression in neurons involved in nociception. The expression of Fos in the neurons could also be mediated by nitric oxide produced from the same, as well as neighbouring neurons, when nociceptive stimulation persisted. Fos-positive neurons in the spinal trigeminal nucleus may project to the thalamus, relaying orofacial nociception to the higher sensory centre.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10650136     DOI: 10.1016/s0006-8993(99)02316-1

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  7 in total

Review 1.  The role of nitric oxide in nociception.

Authors:  Z D Luo; D Cizkova
Journal:  Curr Rev Pain       Date:  2000

2.  Nitric oxide implicates c-Fos expression in the cuneate nucleus following electrical stimulation of the transected median nerve.

Authors:  Hsin-Ying Wang; Yi-Ju Tsai; Seu-Hwa Chen; Chi-Te Lin; June-Horng Lue
Journal:  Neurochem Res       Date:  2011-09-03       Impact factor: 3.996

3.  The effects of the TRPV1 receptor antagonist SB-705498 on trigeminovascular sensitisation and neurotransmission.

Authors:  G A Lambert; J B Davis; J M Appleby; B A Chizh; K L Hoskin; A S Zagami
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-08-19       Impact factor: 3.000

4.  Antinociceptive effect of CNS peroxynitrite scavenger in a mouse model of orofacial pain.

Authors:  Jin-Fei Yeo; Su-Fung Ling; Ning Tang; Wei-Yi Ong
Journal:  Exp Brain Res       Date:  2007-11-21       Impact factor: 1.972

5.  Involvement of endoplasmic reticulum stress in formalin-induced pain is attenuated by 4-phenylbutyric acid.

Authors:  Fan Zhou; Wei Zhang; Jianmei Zhou; Meirong Li; Feng Zhong; Yun Zhang; Yuezhu Liu; Yaping Wang
Journal:  J Pain Res       Date:  2017-03-20       Impact factor: 3.133

6.  Trigeminal Medullary Dorsal Horn Neurons Activated by Nasal Stimulation Coexpress AMPA, NMDA, and NK1 Receptors.

Authors:  P F McCulloch; K M DiNovo; D J Westerhaus; T A Vizinas; J F Peevey; M A Lach; P Czarnocki
Journal:  ISRN Neurosci       Date:  2013-12-08

7.  Orofacial inflammatory pain affects the expression of MT1 and NADPH-d in rat caudal spinal trigeminal nucleus and trigeminal ganglion.

Authors:  Fang Huang; Hongwen He; Wenguo Fan; Yongliang Liu; Hongyu Zhou; Bin Cheng
Journal:  Neural Regen Res       Date:  2013-11-15       Impact factor: 5.135

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.